Skip to main content
. 2023 Mar 28;15(4):1085. doi: 10.3390/pharmaceutics15041085

Figure 3.

Figure 3

Effect of S63845 treatment on myeloid differentiation in CB6F1 mice. (A) Representative FACS profiles (upper panel) and percentages (lower panel) of CMP, GMP, and Mac-1+Gr-1+ subpopulations in BM cells of control and S63845-treated mice on day 7. Control, n = 5; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (B) Representative FACS profiles and percentages of CMP, GMP, and Mac-1+Gr-1+ subpopulations in BM cells of control and S63845-treated mice on day 22. Control, n = 6; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (C) Representative FACS profiles and percentages of CMP, GMP, and Mac-1+Gr-1+ subpopulations in SP cells of control and S63845-treated mice on day 7. Control, n = 5; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (D) Representative FACS profiles and percentages of CMP, GMP, and Mac-1+Gr-1+ subpopulations in SP cells of control and S63845-treated mice on day 22. Control, n = 6; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (E) Representative FACS profiles and percentages of Mac-1+Gr-1+ subpopulations in PB cells of control and S63845-treated mice on day 7. Control, n = 5; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (F) Representative FACS profiles and percentages of Mac-1+Gr-1+ subpopulations in PB cells of control and S63845-treated mice on day 22. Control, n = 6; 25 mg/kg, n = 5; 50 mg/kg, n = 4. All data represent the means ± SEM compared with control unless otherwise specified. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns = not significant according to two-tailed unpaired Students’ t-test. CMP: common myeloid progenitor; GMP: granulocyte-monocyte progenitor; LKS−: Lin−c-Kit+Sca-1−; PB: peripheral blood.